3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasms
2
Mesothelioma
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Ovarian Neoplasms
1
Medical Oncology
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Sunitinib
3
Thymectomy
2
Taxes
2
Prednisone
2
Pemetrexed
2
Paclitaxel
2
Octreotide
2
Imatinib Mesylate
2
Erlotinib Hydrochloride
2
Cisplatin
2
Carboplatin
2
vorolanib
1
regorafenib
1
pembrolizumab
1
olaparib
1
lenvatinib
1
entinostat
1
bosutinib
1
belinostat
1
atezolizumab
1
anetumab ravtansine
1
amrubicin
1
Ramucirumab
1
Radiotherapy
1
Radiosurgery
1
Radiofrequency Ablation
1
Psychiatric Rehabilitation
1
Prednisolone
1
Patient Comfort
1
Palliative Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Thymoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled